Sernova Corp. (TSX:V-SVA) is a clinical-stage company developing products which provide a natural and immune-protected environment for delivering therapeutic cells to patients. Therapeutic cells, such as insulin-producing islets produce and release needed proteins or hormones which are either in short supply or missing from the body. Sernova's products may benefit patients with chronic metabolic, neurological, and haematological diseases.
The first therapeutic focus of Sernova is insulin-dependent diabetes. Sernova takes part in the near-term $8 billion cell therapy market.
Sernova, is developing two novel closely integrated proprietary platform technologies.
The first is the Cell Pouch System™, a scalable device providing a natural "organ-like" environment for therapeutic cells such as insulin producing islets for diabetics and the second is Sertolin™, a cell-based technology providing an immune-privileged environment for donor cells, reducing or eliminating the need for anti-rejection drugs.
Using a medical device and combination product strategy Sernova partakes in the rapidly expanding cell therapy market which positions the company for significant growth and revenue upon commercialization of its "paradigm-shifting" technology.
Sernova's team is immediately focused development of the Cell Pouch System™ for treatment of insulin-dependent diabetes which could benefit both Type-1 and many Type-2 patients, currently at 9m North American patients and plans to commercialize products for Parkinson's, spinal cord injury, and haemophilia among other debilitating diseases.
Sernova holds exclusive rights to multiple patents and associated intellectual property for the therapeutic use of Sertoli cells and has filed patents on the Cell Pouch System™.
